BioCentury | May 30, 2016
Company News

Astellas, Thunderbolt deal

...Newco Thunderbolt acquired Astellas’ preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF...
...to treat B cell-mediated disorders, including systemic lupus erythematosus (SLE). The terms are not disclosed. Thunderbolt...
...development costs of the BAFF/TNF program. Velocity said Astellas received an undisclosed equity stake in Thunderbolt...
BioCentury | May 26, 2016
Company News

Vitesse launches first newco Thunderbolt

...Vitesse Biologics LLC (South San Francisco, Calif.) launched virtual newco Thunderbolt Pharma Inc. (South San Francisco, Calif.), which...
...13 ( TNFSF13 ; APRIL) to treat B cell-mediated disorders including systemic lupus erythematosus (SLE). Thunderbolt...
...SVP of Business Development Stuart Sedlack said Astellas received an undisclosed equity stake in Thunderbolt. Thunderbolt...
Items per page:
1 - 2 of 2
BioCentury | May 30, 2016
Company News

Astellas, Thunderbolt deal

...Newco Thunderbolt acquired Astellas’ preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF...
...to treat B cell-mediated disorders, including systemic lupus erythematosus (SLE). The terms are not disclosed. Thunderbolt...
...development costs of the BAFF/TNF program. Velocity said Astellas received an undisclosed equity stake in Thunderbolt...
BioCentury | May 26, 2016
Company News

Vitesse launches first newco Thunderbolt

...Vitesse Biologics LLC (South San Francisco, Calif.) launched virtual newco Thunderbolt Pharma Inc. (South San Francisco, Calif.), which...
...13 ( TNFSF13 ; APRIL) to treat B cell-mediated disorders including systemic lupus erythematosus (SLE). Thunderbolt...
...SVP of Business Development Stuart Sedlack said Astellas received an undisclosed equity stake in Thunderbolt. Thunderbolt...
Items per page:
1 - 2 of 2